Leukocytoclastic vasculitis and desensitization to high-dose methotrexate in primary central nervous system lymphoma

The backbone drug in the management of primary central nervous system lymphoma (PCNSL) is systemic high-dose methotrexate (HD MTX). This case report describes a previously healthy 56-year old man diagnosed with PCNSL who developed a severe leucocytoclastic vasculitis that was clinically consistent with HD MTX toxicity. He was given a premedication regimen along with a desensitization protocol for HD MTX that permitted the administration of additional cycles of HD MTX without further serious adverse events.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 19, 2018 Category: Hematology Authors: Colette Hanna, Diego Villa, Carla Irani, Marwan Ghosn, Elie El Rassy Tags: Case Report Source Type: research